search

Active clinical trials for "Carcinoma, Hepatocellular"

Results 2241-2250 of 2402

Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

CirrhosisHepatocellular Carcinoma

Although serum alpha-fetoprotein level and abdominal sonography are the main methods to screening hepatocellular carcinoma (HCC) in cirrhotic patients, the adequate time and methods used are not completely well-defined. This study aims to assess the better timing and methods for prospectively screening HCC in patients with cirrhosis

Completed2 enrollment criteria

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus < = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.

Completed6 enrollment criteria

Himalaya Early Access Program

Unresectable Hepatocellular Carcinoma

To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with unresectable HCC.

Approved for marketing67 enrollment criteria

Predictive Power of Share Wave Fibro Scan in HCC After HCV Infection

Hepatocellular Carcinoma

Shear wave electrography score allows stratification of HCC risk in a noninvasive and reliable way and can guide the surveillance strategy for HCC in patients with CLD

Completed2 enrollment criteria

Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

Hepatocellular Carcinoma Resectable

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

Completed2 enrollment criteria

Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma

Hepatocellular Carcinoma

The aim of this study is to evaluate the hepatic perfusion computer tomography and dual energy computer tomography in the assessment of tumor characterization of Hepatocellular carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative parameters computer tomography obtained with the pathological data of the surgical specimens.

Unknown status9 enrollment criteria

Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma...

Hepatocellular Carcinoma

To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea

Completed3 enrollment criteria

Hepatocellular Carcinoma Growth and Molecular Aggressiveness

CirrhosisHepatocellular Carcinoma

Our long-term objective is to develop a new tool based on a (molecular-biology) integrated imaging technology able to characterize and categorize hepatocellular carcinoma (HCC) patients in need of liver transplant (LT). To this end, our study aims at correlating specific imaging traits and fractional growth of individual tumors collected over a restricted time frame (T0 and at week 7 after first tumor detection), with a "molecular signature", obtained by custom microarray, histochemical and cytokine analysis. This should allow us to translate a series of purely morphologic information into a meaningful pathobiologic data sets. Validation of the integrated molecular-imaging tool will be performed prospectively by correlating the imaging-molecular data with HCC outcome in term of survival and disease-free survival after down staging procedures.

Completed7 enrollment criteria

TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)

Unresectable Hepatocellular CarcinomaUndergoing Chemoembolization and Radioembolization

The purpose of this research study is to evaluate the quantitative information of utilizing C-arm systems in liver tumor care in hopes this potential clinical combination of imaging could aid in diagnosis and evaluation of tumor therapy.

Completed16 enrollment criteria

Diffusion-Weighted Magnetic Resonance Imaging

Hepatocellular CarcinomaSpine Metastasis

Recently, diffusion-weighted (DW) MR imaging has widened its application on various oncologic applications. Especially, it is expected the DW MRI could provide valuable information about early response evaluation after treatment using rapid apparent diffusion coefficient (ADC) value change. It has demonstrated potential usefulness in response evaluation in the liver tumors after treatments such as transarterial chemoembolization (TACE) and radiation therapy (RT). Furthermore, it is a functional imaging technique that does not require a contrast agent, it can be safely used in patients with renal insufficiency or other medical contraindications for contrast agents. The optimal assessment of early response of RT could provide one of the most important information to prescribe patient and cancer specific RT dose. It might be also important in palliative RT of HCC bone metastasis which is related with painful aggressive mass formation. This study is performed to evaluate the usefulness of DW MRI in early response evaluation after RT for HCC bone metastasis.

Unknown status10 enrollment criteria
1...224225226...241

Need Help? Contact our team!


We'll reach out to this number within 24 hrs